Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pachyman is a naturally occurring beta-glucan polysaccharide extracted from the sclerotium of the edible medicinal fungus *Poria cocos* (Fuling). Chemically, it consists of a beta-(1→3)-D-glucan backbone with beta-(1→6)-D-glucan branches. Pachyman acts as a ligand for C-type lectin domain family 7 member A (Dectin-1), a pattern-recognition receptor expressed on myeloid cells and certain T-cell subpopulations. Research led by Johns Hopkins University has demonstrated that oral administration of pachyman modulates the gut-immune-brain axis, inhibiting the activation of colonic Dectin-1+ macrophages and gamma-delta 17 T cells. This mechanism has been shown to reverse psychosocial and cognitive deficits, social avoidance, and depressive-like behaviors in preclinical models of chronic social defeat stress and EcoHIV infection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pachyman.